Login to Your Account

Other news to note

Wednesday, August 6, 2014
Genoa Pharmaceuticals Inc., of San Diego, said the FDA has granted orphan-drug designation to Genoa for the use of pirfenidone in their lead program, inhaled GP-101 for the treatment of idiopathic pulmonary fibrosis (IPF).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription